Fresenius Kabi Recalls Sensorcaine-MPF Injection, USP
The company voluntarily recalls product due to particulate matter.
Fresenius Kabi USA (Lake Zurich, IL) announced on April 25, 2016 that it is voluntarily recalling a single lot of Sensorcaine-MPF (bupivacaine HCI) Injection, USP, 0.75%, 7.5 mg/mL, 30 mL in a 30mL vial due to visible particulate matter that was observed during a company inspection of reserve samples. The particulate has been characterized as glass. The affected lot (lot number 6111504; product code 470237; expiration September 2019) was shipped in the United States to wholesaler and distributer outlets between March 4–21, 2016. The company has not received any reports of adverse events as of April 25, 2016.
According to the company, Sensorcaine-MPF (bupivacaine HCl) Injection is “indicated for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures and for obstetrical procedures.” Glass particulate matter in the solution may result in inflammation and injury if administered by the epidural or retrobulbar route, according to the company, or possibly cause blockage of vasculature around the eye or emboli in the vasculature of eye nerves.
Distributors and customers have been notified of the recall and healthcare facilities have been advised to discontinue distribution and use of the lot. Adverse events or quality problems may be reported to FDA’s MedWatch Adverse Event Reporting program.
Source: FDA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
